Aurobindo Pharma Limited — Updates, 04-08-2025: Press Release

Aurobindo Pharma reported Q1 results with Revenue from Operations up 4% YoY to INR 7,868 Cr. Europe formulations surged 18% to INR 2,338 Cr, and ARV revenue soared 55.2% to INR 355 Cr. US formulations saw a marginal 1.9% decline to INR 3,488 Cr, impacted by destocking. API revenue decreased 16.1% to INR 916 Cr. Net Profit stood at INR 824 Cr, down 10.2% YoY. The company received 14 USFDA final approvals and launched 15 products, boosting its commercial footprint. An interim dividend of INR 4.0 per share was approved.